Clinical trial · Observational
Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy
RETRACE Study - Retrospective Observational Study Evaluating Disease Characteristics and Treatment Landscape of High-risk Locally Advanced (LA) or Recurrent / Metastatic (R/M) Cervical Cancer in Italy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Locally Advanced Cervical Cancer | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Cervical Cancer | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
| Recurrent Cervical Cancer | Malignant Cervical Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- The proportion of patients receiving each different treatment pattern of LA, recurrent, and metastatic CC (%)
- timeFrame
- Retrospective data capture from Jan 2018 to Dec 2021
- description
- Baseline and demographic characteristics will be summarized by standard descriptive summaries using absolute frequencies and proportions (%).
- measure
- The proportion of patient with recurrence or dead after treatment and remission (%)
- timeFrame
- Retrospective data capture from Jan 2018 to Dec 2021
- description
- Baseline and demographic characteristics will be summarized by standard descriptive summaries using absolute frequencies and proportions (%).
- measure
- Median time from remission to recurrence
- timeFrame
- Retrospective data capture from Jan 2018 to Dec 2021
- description
- The study aim is to describe the time from curative intervention to recurrence (for patients who had a curative surgery). Time to recurrence will be calculated and represented using Kaplan-Meier curves and summarized using median with 95% confidence interval.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF) * Age ≥18 years * Diagnosis of a cervical cancer * Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease * Any treatment received between January 2018 and December 2021 for advanced disease Exclusion Criteria: * Patients participating in a pharmacological clinical trial for the treatment of advanced disease * Patients who participated in a clinical trial * Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs
References
Publications (0)
Data not yet available